Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
7.12% $2.86
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 45.71 mill |
EPS: | -0.790 |
P/E: | -3.62 |
Earnings Date: | Jun 09, 2024 |
SharesOutstanding: | 15.98 mill |
Avg Daily Volume: | 0.103 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.62 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.62x |
Company: PE -3.62 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.005 (-64.86%) $-1.855 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 2.57 - 3.15 ( +/- 10.24%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-12-28 | Bondarenko Jamieson | Buy | 28 000 | Common Shares |
2022-12-23 | Williams William V. | Buy | 2 530 | Warrant |
2022-12-20 | Bondarenko Jamieson | Buy | 22 000 | Common Shares |
2022-08-01 | Bondarenko Jamieson | Sell | 0 | Common Shares |
2021-03-29 | Bondarenko Jamieson | Sell | 150 000 | Option (Right to Buy) |
INSIDER POWER |
---|
-71.72 |
Last 25 transactions |
Buy: 52 530 | Sell: 1 209 572 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.86 (7.12% ) |
Volume | 0.0872 mill |
Avg. Vol. | 0.103 mill |
% of Avg. Vol | 84.32 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.